Effect of polaprezinc vs zinc acetate dihydrate in Patients Receiving Hemodialysis With Zn deficiency; a single center, open label, randomized clinical study

Effect of polaprezinc vs zinc acetate dihydrate in Patients Receiving Hemodialysis With Zn deficiency; a single center, open label, randomized clinical study - Effect of polaprezinc vs zinc acetate dihydrate in Patients Receiving Hemodialysis With Zn deficiency; a single center, open label, randomized clinical study

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000031200

Enrollment

110

Registered

2018-02-08

Start date

2018-04-11

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Patients on maintenance hemodialysis with zinc deficiency

Interventions

zinc acetate dihydrate 25mg twice a day, for 24 weeks Polaprezinc 75mg twice a day, for 24 weeks

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1. Hemodialysis patients, hemodialysis vintage >6months, with serum levels of zinc <70 microgram/dL 2.Age of >20 years old 3. Patients who are able to understand contents of this trial and give written informed consents

Exclusion criteria

Exclusion criteria: 1. Hemodialysis vintage of <6 months 2. Already priscribed polaprenzinc or zinc acetate dihydrate 3. Unwillingness to participate in the study 4. Recent active infection 5. End stage of malignancy 6. Previous history of blood transfusion within at least 3 months before the trial 7. Severe liver damage 8. Drug/alcohol abuse 9. Patients who are not appropriate for the tial

Design outcomes

Primary

Measure	Time frame
The cahnge in the serum levels of zinc 6 months after the trial	—

Secondary

Measure	Time frame
The change in Erythropoeisis stimulant agent resistance 6 months after the trial The change in the serum levels of copper 6 months after the trial	—

Countries

Japan

Contacts

Public ContactShingo Hatakeyama

Dept. of Urology, Hirosaki University Graduate School of Medicine Department of Urology

shingorilla2@gmail.com0172395091

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026